NASDAQ: BIIBBiogen Inc Stock Ownership - Who owns Biogen?
Insider buying vs selling
Have Biogen Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Priya Singhal | Head of Development | 2025-09-02 | 517 | $133.55 | $69.05kSell |
| Priya Singhal | Head of Development | 2025-08-29 | 807 | $132.22 | $106.70kSell |
| Rachid Izzar | Head of Global Product Strat. | 2025-07-08 | 2,223 | $135.00 | $300.11kSell |
| Priya Singhal | Head of Development | 2025-05-19 | 3,806 | $126.25 | $480.51kSell |
| Caroline Dorsa | Director | 2025-05-02 | 1,235 | $122.72 | $151.56kBuy |
| Adam Keeney | Head of Corporate Development | 2025-05-01 | 454 | $120.93 | $54.90kSell |
| Stephen A. Sherwin | Director | 2025-03-07 | 8,760 | $150.02 | $1.31MSell |
| Priya Singhal | Head of Development | 2025-02-10 | 357 | $142.54 | $50.89kSell |
| Susan H. Alexander | EVP Chief Legal Officer | 2025-02-10 | 807 | $142.54 | $115.03kSell |
| Robin Kramer | Chief Accounting Officer | 2025-02-10 | 245 | $142.54 | $34.92kSell |
BIIB insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when BIIB insiders and whales buy or sell their stock.
BIIB Shareholders
What type of owners hold Biogen Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Vanguard Group Inc | 11.79% | 17,290,651 | $2.50B | Institution |
| Primecap Management Co | 10.78% | 15,802,122 | $2.29B | Institution |
| Blackrock Inc | 9.25% | 13,555,466 | $1.96B | Institution |
| State Street Corp | 5.09% | 7,468,807 | $1.08B | Institution |
| Wellington Management Group LLP | 3.27% | 4,798,420 | $695.10M | Institution |
| Geode Capital Management LLC | 2.67% | 3,918,150 | $567.58M | Institution |
| Point72 Asset Management LP | 2.61% | 3,831,727 | $555.06M | Institution |
| Invesco Ltd | 1.58% | 2,320,126 | $336.09M | Institution |
| Norges Bank | 1.54% | 2,264,177 | $327.99M | Institution |
| Morgan Stanley | 1.33% | 1,956,210 | $283.38M | Institution |
BIIB vs General Drug Manufacturer Stocks
Biogen Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.